Active clinical trial

Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)

Study Status: 
Active
Study Description: 

The purpose of this clinical trial is to evaluate the efficacy, safety and tolerability of solaneuzumab, a drug that may have the potential to slow the onset of Alzheimer's disease (AD). In AD, there are abnormally high levels of a protein, called amyloid in the brain. We hope that solaneuzumab can reduce the amount of amyloid in the brain.

 

We are looking for participants who:

-- do not have memory problem

-- are between age 65 and 85

-- have a reliable caregiver or family member who knows them well

-- are in stable medical condition

-- are willing to undergo MRI and PET scans

 

More information is attached.

Study Coordinator(s): 

Sehily Jaimes

Tel:  617-643-5200

Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) versus Placebo

Study Status: 
Active
Study Description: 

The purpose of this study is to find out if a new drug called Solanezumab can help people with Alzheimer's disease (AD). We also want to find out if Solanezumab is safe to take without causing too many side effects. In AD, amyloid fragments gather and form hard plaques. Doctors think that amyloid can cause symptoms such as memory loss and confusion. We hope that Solanezumab can reduce the amount of amyloid in the brain.

 

Who is eligible?

Please see attached.

Study Coordinator(s): 

Sehily Jaimes

Tel:  617-643-5200

Therapeutic Effects of Intranasally-Administered Insulin in Adults with Amnestic Mild Cognitive Impairment (aMCI) or Mild Alzheimer's Disease (AD) (ADC-046-INI)

Study Status: 
Active
Study Description: 

The purpose of this study is to find out if a type of insulin (Humulin® R) improves memory when it is given intranasally (as a "nasal spray") to adults with a mild cognitive (memory) impairment or early Alzheimer's disease (AD). This study will also look at the effect of intranasal insulin (INI) has on the brain structure and function and markers of AD in the cerebrospinal fluid (CSF) and blood.

 

More information is attached.

 

Study Coordinator(s): 

Sehily Jaimes

Tel:  617-643-5200

Disentangling the Contribution of Tau to Aging, Dementia, and Neurodegeneration

Study Status: 
Active
Study Description: 

Researchers from the Massachusetts General Hospital (MGH) ducting a research study to study the way brains change with age.   

 

You may be eligible to participate if you:

-- are age 20 to 90 and speak English

 

This research study involves:

-- up to 6 visits to the MGH over 6 months

-- evaluations, including memory tests and brain scans

 

You will receive:

-- up to $700 for participating in the total study ($50 - $200 paid per visit)

-- assistance with transportation as needed

-- dedicated relationships with research doctors and study team members

Study Coordinator(s): 

Sehily Jaimes

Tel:  617-643-5200

A Randomized, 18-Week, Placebo-Controlled, Double-Blind, Parallel-Group Study of the Safety and Efficacy of PF-05212377 (SAM-760) in Subjects with Mild to Moderate AD with Existing Neuropsychiatric Symptoms on a Stable Daily Dose of Donepezil

Study Status: 
Active
Study Description: 

The purpose of this clinical trial is to evaluate the safety of PF-05212377 (SAM-760) and the effect of PF-05212377 (SAM-760) on cognition and some behavioral symptoms associated with Alzheimer's disease.

 

We are looking for participants who:

 

-- have a diagnosis of Alzheimer's disease

-- are age 60 or older

-- have a reliable caregiver or family member who is able to accompany them to study visits

-- are in stable medical condition

-- are on stable doses of Aricept (donepezil)

-- are not on any other medications for Alzheimer's disease (antidepressants are allowed)

 

More information is attached.

Study Coordinator(s): 

Sehily Jaimes

Tel:  617-643-5200

A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-Finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects with Early Alzheimer's Disease (BAN2401-G000-201)

Study Status: 
Active
Study Description: 

What is the purpose of this research study?

The purpose of this clinical trial is to evaluate the efficacy, safety and tolerability of BAN2401, a drug that may have the potential to treat Alzheimer's disease (AD). In AD, there are abnormally-high levels of a protein, called amyloid beta, in the brain. We hope that BAN2401 can reduce the amount of amyloid.

 

Who is eligible?

We are looking for participants who:

-- have been diagnosed with Mild Cognitive Impairment (MCI) or mild Alzheimer's disease dementia

-- are between the age of 50 and 90

-- have a reliable caregiver or family member who knows them well and is able to accompany them to study visits

-- are in stable medical condition

-- are willing to undergo MRI and PET scans and optional lumbar punctures

 

People taking approved Alzheimer's medications (donepezil/Aricept, galantamine/Razadyne, rivastigmine/Exelon, memantine/Namenda) are eligible to take part in this study and can continue taking these medications during the study.

 

Please see the attached study description for more information.

Study Coordinator(s): 

Sehily Jaimes

Tel:  617-643-5200

Dominantly-Inherited Alzheimer Network (DIAN)

Study Status: 
Active
Study Description: 

What is DIAN?

DIAN stands for the Dominantly Inherited Alzheimer’s Network.  This international network has been established by the National Institute on Aging of the National Institutes of Health (US) to bring together researchers who study genetic forms of Alzheimer’s disease (AD). 

 

The DIAN research volunteers are members of families in which AD is dominantly-inherited, meaning that about 50% of the individuals in each generation of a family develop AD, generally before age 60.  These rare forms of AD are caused by a mutation in one of 3 genes.  Each child of an affected parent has a 50% chance of inheriting the mutation.  If they do, they will develop the dementia of AD at about the same age as their parent.  Siblings who do not have the mutation have no greater risk of developing AD than someone without a family history of AD and will participate in DIAN as part of a comparison group for their mutation-carrying siblings.

 

Please see the attached study description for more information.

 

Study Coordinator(s): 

Sehily Jaimes

Tel:  617-643-5200

Implications of Amyloid Deposition in Clinically Normal Older Individuals

Study Status: 
Active
Study Description: 

We are seeking healthy adults, 60 to 90 years of age to participate in a research study. The purpose of the study is to develop ways for understanding memory changes that occur with age. Participants will be asked questions about their memory and must have a friend or relative who can answer ten minutes of questions over the telephone about day-to-day activities.

 

If you qualify, you will be asked to have 3 brain scans and follow-up memory testing annually for five years after your first testing. All evaluations will be free of cost and reimbursement for time and transportation is $750 if you complete all visits. All information is kept completely confidential.

 

Study Coordinator(s): 

Sehily Jaimes

Tel:  617-643-5200

Evolution of Memory-Related fMRI Activation Over the Course of MCI & AD

Study Status: 
Active
Study Description: 

We are seeking healthy volunteers and individuals with Mild Cognitive Impairment (MCI) or Mild Alzheimer's Disease (AD) who are interested in taking part in a clinical research study to find out if functional MRI images of the brain can be used to diagnose and monitor the course and treatment of MCI and AD. Subjects must have a study partner and be willing to come to six to eight clinic visits over the course of two to three years.

 

At each of these visits, subjects will be asked to have blood drawn, undergo tests of memory and have an MRI scan of the brain. Each visit will last between four to five hours. Study participants will be reimbursed $50.00 for the completion of each scan visit and for parking.  All information is kept completely confidential.

 

ELIGIBILITY CRITERIA

 

Inclusion criteria:

1. Fifty-five to ninety years of age.

2. Healthy volunteer (MMSE 27-30) or patient with a diagnosis of MCI (MMSE 26-30) or Mild AD (MMSE 20-26).

 

Exclusion criteria:

1. Significant neurological disease other than Alzheimer's disease.

2. Clinically-significant and/or un-controlled medical condition.

3. History of alcohol abuse or dependence within the past two years.

4. Participation in another clinical research trial in which memory tests are being collected more than one time per year.

Study Coordinator(s): 

Sehily Jaimes

Tel:  617-643-5200

Syndicate content